[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors by Lechner, Christian et al.
molecules
Article
[b]-Annulated Halogen-Substituted Indoles as
Potential DYRK1A Inhibitors
Christian Lechner 1,2, Maren Flaßhoff 1, Hannes Falke 1, Lutz Preu 1, Nadége Loaëc 3,4,
Laurent Meijer 4 , Stefan Knapp 5 , Apirat Chaikuad 5 and Conrad Kunick 1,2,*
1 Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig,
Beethovenstraße 55, 38106 Braunschweig, Germany
2 Zentrum für Pharmaverfahrenstechnik (PVZ), Technische Universität Braunschweig, Franz-Liszt-Straße 35A,
38106 Braunschweig, Germany
3 Faculté de Médecine et des Sciences de la Santé UBO, 22 avenue Camille Desmoulins, 29200-Brest, France
4 ManRos Therapeutics & Perha Pharmaceuticals, Perharidy Research Center, 29680 Roscoff, France
5 Institute for Pharmaceutical Chemistry and Buchmann Institute for Molecular Life Sciences, Johann
Wolfgang Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany
* Correspondence: c.kunick@tu-bs.de; Tel.: +49-531-391-2754
Academic Editor: David StC Black
Received: 12 September 2019; Accepted: 7 November 2019; Published: 13 November 2019


Abstract: Since hyperactivity of the protein kinase DYRK1A is linked to several neurodegenerative
disorders, DYRK1A inhibitors have been suggested as potential therapeutics for Down syndrome
and Alzheimer’s disease. Most published inhibitors to date suffer from low selectivity against related
kinases or from unfavorable physicochemical properties. In order to identify DYRK1A inhibitors
with improved properties, a series of new chemicals based on [b]-annulated halogenated indoles were
designed, synthesized, and evaluated for biological activity. Analysis of crystal structures revealed a
typical type-I binding mode of the new inhibitor 4-chlorocyclohepta[b]indol-10(5H)-one in DYRK1A,
exploiting mainly shape complementarity for tight binding. Conversion of the DYRK1A inhibitor
8-chloro-1,2,3,9-tetrahydro-4H-carbazol-4-one into a corresponding Mannich base hydrochloride
improved the aqueous solubility but abrogated kinase inhibitory activity.
Keywords: DYRK1A; indole; molecular docking; protein kinase inhibitor; solubility; nephelometry;
X-ray structure analysis
1. Introduction
The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is the most
prominent member of the DYRK group of kinases [1]. DYRK1A is involved in elementary physiological
processes such as neuronal differentiation [2], apoptosis [3,4], cell cycle regulation [5], transcription
regulation [6], splicing [7], EGFR stabilization [8] and synaptic processes [9]. dyrk1a gene is located
within the Down syndrome (DS) critical region on the human chromosome 21. Individuals with
trisomy 21 exhibit a 1.5-fold expression of DYRK1A compared to subjects with only two chromosome
21 copies. The characteristic symptom of Down syndrome, intellectual disability, has been linked to this
overexpression of DYRK1A [10–12]. Overexpression of DYRK1A is also involved in the formation of
the neurotoxic β-amyloid plaques and hyperphosphorylation of the tau-protein as seen in Alzheimer’s
disease. In accordance with these observations, DS individuals frequently show an early onset of
AD [11–13].
Based on the pathological consequences of increased DYRK1A activity, the enzyme has been
suggested as a therapeutic drug target for treatment of DS and AD [10–12]. Thus, various small
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molecules representing a broad variety of chemotypes were described as DYRK1A inhibitors in recent
years [12,14–16].
DYRKs belong to the CMGC kinase family and are structurally related to cyclin-dependent
kinases (CDKs), mitogen-activated protein kinases (MAPKs), glycogen synthase kinases (GSKs) and
cdc2-like kinases (CLKs) [17]. Since all members of the CMGC group bind ATP in their catalytic
domain, the structural differences within the ATP binding site are low. The closest structural relatives
of DYRK1A are DYRK1B (85% overall similarity) and CLK1 (30% overall similarity). The catalytic
domain of DYRK1B differs by just one amino acid in the hinge region from DYRK1A and the binding
pocket of CLK1 has a similarity of 70% compared to DYRK1A [18]. Hence, the design of selective and
potent inhibitors for individual members of the CMGC group is challenging, and consequently many
of the DYRK1A inhibitors published to date exhibit only a limited degree of selectivity.
Harmine (1), a β-carboline alkaloid, is a strong DYRK1A inhibitor but, due to inhibition of
monoamine-oxidase A (MAO-A), is not suitable as drug candidate [19]. Leucettine L41 (2), derived
from the marine natural product leucettamine B, is a dual DYRK1A/CLK1 inhibitor and one of the
pharmacologically best profiled DYRK1A inhibitors [20–26]. The halogenated indole derivative
KH-CB19 (3) also inhibits CLK1 and DYRK1A [27]. The benzothiazole derivatives INDY (inhibitor
of DYRK, 4), proINDY (5), and TG003 (6) showed a comparable inhibitory activity and selectivity
profile to 1, but 4 showed no MAO-A inhibition [28,29]. A class of DYRK1A inhibitors with remarkable
potency is represented by EHT 5372 (7), which exhibited subnanomolar activity on DYRK1A and
DYRK1B [30,31]. The DYRK1A-inhibitor F-DANDY (8) was reported to show efficacy in DS mice [32].
A particular mechanism of inhibition is displayed by FINDY (9) which is targeting the DYRK1A folding
process by selective inhibition of autophosphorylation on Ser97 [33] (Figure 1).
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KuFal194 (10) is a potent DYRK1A inhibitor (IC50DYRK1A = 6 nM) which displays reasonable
selectivity versus DYRK1B (IC50DYRK1B = 600 nM) and CLK1 (IC50CLK1 = 500 nM). Despite
a high in vitro activity of 10, the activity in cellular DYRK1A inhibition assays (IC50 = 2.1 µM)
was unsatisfactory [34]. The disparity between in vitro and in cellulo activity of 10 was explained
by a low cellular uptake due to its poor physicochemical properties [35]. Representing a 7-
halogenated indole derivative, the iodo-substituted indolo[3,2-c]quinoline 10 structurally resembles
the dichloro-substituted inhibitor KH-CB19 (3).
In order to improve the physicochemical properties of 10 by downsizing the structure, the
[b]-annulated chloro-substituted indoles 11–15 were designed [36] (Figure 2). Although in the series
of indolo[3,2-c]quinoline-6-carboxylic acids related to compound 10 the iodo-substituted analogues
had shown a stronger effect, chloro-substituted compounds were prepared for the study presented
here. The main reason for this was that compared to iodine, chlorine increases molar mass and
lipophilicity less strongly and is also less toxicologically problematic. In addition, chlorine compounds
are easier to synthesize than their iodine analogues. Prior to synthesis, the fitting probabilities of the
structures to the ATP binding pocket of DYRK1A were evaluated by docking analyses, employing
the published X-ray structure of 10 in DYRK1A as template [34]. For improvement of solubility,
the Mannich base hydrochloride 16 was derived from 13. Testing of these new [b]-annulated indoles
revealed 4-chlorocyclohepta[b]indol-10(5H)-one (11) as a novel submicromolar dual CLK1/DYRK1A
inhibitor. The binding mode of inhibitor 11 as predicted by previous docking studies was confirmed
by an X-ray structure analysis of the DYRK1A-ligand complex.
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2. Results and Discussion
2.1. Structure Design Considerations and Docking Analyses
In all newly designed analogues, a halogen substituent was retained, since it was shown
previously that such a substitution motive is important for DYRK1A inhibitory activity [34]. When the
so-designed molecules 11–16 were docked into the structure of the DYRK1A-10 complex (PDB:4YLJ), all
congeners fitted nicely into the ATP binding pocket and displayed similar poses as the actual ligand 10.
For example, the docked cyclohexenone analogue 13 was located near the hinge region in the adenine
binding area, displaying a hydrogen bond to the terminal amino group of the conserved Lys188. Similar
to 10, 13 is not forming direct hydrogen bonds to the hinge, but straightens its halogen substituent
towards the backbone carbonyl oxygen of Leu241, albeit the distance of 4.8 Å between chlorine and
oxygen appears too large for a halogen bond (Figure 3a). During later studies, co-crystals of the
analogue 11 with the DYRK1A were produced (see below). The structure of the DYRK1A-11 complex as
established by X-ray analyses showed a similar overall orientation as predicted by the docking results
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for all analogues with the hydrogen bond between the carbonyl oxygen of the ligand and Lys188 as well
as the chloro substituent alignment towards Leu241. In this case, the distance of halogen and oxygen is
closer (3.9 Å) but still not fulfilling the requirements for strong halogen bonding (Figure 3c). Although
compounds such as 11 and 13 are smaller and less lipophilic compared to the model structure 10, they
proved to be poorly soluble. To improve the solubility, a piperidinomethyl side chain was atttached
to the 3-position of ligand 13. When the resulting derivative 16 was docked into DYRK1A, only the
(S)-isomer adopted the canonical orientation observed for the aforementioned congeners (Figure 3b).
In contrast, the (R)-isomer displayed an orientation with a flipped tetrahydrocarbazolone motive which
nevertheless fitted the ATP binding site (Figure 3d). In the docking poses, both enantiomers of 16
displayed additional hydrogen bonds between the protonated piperidine nitrogen and the backbone
carbonyl oxygen of Asn292.
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Figure 3. Orientations of [b]-annulated indoles in the ATP binding pocket of DYRK1A. (a) Orientation
of 13 predicted by a docking analysis in DYRK1A (pdb: 4YLJ). (b) Orientation of (S)-16 predicted by
a docking analysis in DYRK1A (pdb: 4YLJ). (c) Result of an X-ray structure analysis of DYRK1A in
complex with 11 (pdb: 6T6A). Note that the orientation of the ligand is very similar to the poses of
13 and (S)-16 as predicted by the docking analyses. (d) Orientation of (R)-16 predicted by a docking
analysis in DYRK1A (pdb: 4YLJ). Note that the orientation of the tetrahydrocarbazolone ring system
is flipped so that the indole nitrogen points inward and the carbonyl oxygen points outward of the
binding pocket.
2.2. Syntheses
2-Chlorophenylhydrazine hydrochloride (17) and cyclopentanone (18) were reacted in a Fischer indole
synthesis to yield the c clope tane-annulate indole 20 [37] which upon oxidation with 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) furnished 5-chloro-3,4-dihydrocyclopenta[b]in-dol-1(2H)-one
(12) [38]. The Fischer reaction of cycloheptanone (19) wit 2-chloro-phenylhydrazine was carried
out in a low melting mixture of (l)-tartaric acid and N,N’-dimethylurea [39] since
conventional reaction conditions furnished only small yields with these starting materials.
The resulti g annulated i ole 21 was oxidized with DDQ yielding the ketone 22. The following
aromatizatio of 22 with phenyltrimethylammonium tribromide (PTAB) and lithium c loride gave
4-chlorocyclohepta[b]indol-10(5H)-one (11) (Scheme 1).
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Scheme 1. Synthesis of 4-chlorocyclohepta[b]indol-10(5H)-one (11) and 5-chloro-3,4-dihydrocyclopenta
[b]indol-1(2H)-one (12). Reagents and conditions: (a) glacial acetic acid, H2SO4, 90–110 ◦C, 2 h,
63% (20) or (l)-tartaric acid, N,N’-dimethylurea (30:70), 70 ◦C, 3 h (21%, 21); (b) 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ), 0 ◦C→rt., 1–3 h, 52% (12) and 64% (22); (c) 1. PTAB, THF, rt., 48 h;
2. LiCl, DMF, reflux, 2.5 h (58%).
The cyclohexanone-annulated indole 13 was prepared by Fischer indole reaction from
cyclohexane-1,3-dione (23) in aqueous sulfuric acid. For the preparation of lactames, the cyclic
ketones 12 and 13 were converted into the oximes 24 and 25, respectively. A subsequent Beckmann
rearrangement in hot polyphosphoric acid afforded the desired ring enlarged products 14 and 15.
For the preparation of the Mannich base hydrochloride 16, the classical reaction with formaldehyde
and secondary amine afforded poor product yields. Therefore, the cyclic ketone 13 was initially
converted into the α,β-unsaturated ketone 26 by reaction with N,N-dimethylmethylene iminium
chloride. Nucleophilic addition of piperidine to 26 and subsequent treatment with hydrogen chloride
afforded the desired salt 16 (Scheme 2).
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Scheme 2. Synthesis procedures for [b]-annulated halogen-substituted indoles. Reagents and conditions:
(a) 1. H2O, rt., 24 h; 2. H2SO4 (20%, v/v), 100 ◦C, 2 h (31%); (b) hydroxylamine hydrochloride (2-3 eq),
sodium acetate (2-3 eq), EtOH/H2O, 120 ◦C (64% (24), 27% (25)); (c) polyphosphoric acid, 140 ◦C,
1 h (42% (14), 45% (15)); (d) N,N-dimethylmethylene iminium chloride, DMF, 130 ◦C, 2 h (74%),
(e) 1. 1,4-dioxane/water (1:1), piperidine, 55 ◦C, 16 h; 2. propan-2-ol, HCl, Et2O (59%).
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2.3. Kinase Inhibitory Activity
The new compounds 11–16 were tested on an array of protein kinases of the CMGC family. First,
the kinases were incubated with 10 µM solutions of the test compounds and the residual activities
compared to controls were measured. The IC50 values of promising compounds were then determined
from concentration-response curves (Table 1).
Table 1. Inhibition of protein kinases by [b]-annulated chloroindoles. IC50 values (µM) 1.
Entry. CDK1 CDK2 CDK5 CDK9 CK1 CLK1 DYRK1A GSK-3
10 >10 >10 >10 >10 >10 0.50 0.006 >10
11 >10 >10 >10 >10 >10 0.17 0.20 >10
12 >10 >10 >10 >10 >10 0.89 0.71 >10
13 n.t. n.t. 8.2 n.t. >10 0.30 1.6 4.4
14 1.2 1.7 0.81 0.88 3.6 0.12 0.19 2.7
15 7.0 2.5 2.5 2.2 4.2 0.32 2.2 >10
16 n.t. n.t. n.t. n.t. n.t. n.t. >10 n.t.
1 Results from dose response curves. Data points were recorded as triplicates. n.t. = not tested. Standard deviation
of data points of single concentrations was typically below 10%. Assays were performed by radiometric methods,
with the exception of 16, which was tested using the ADP-GloTM assay kit (Promega, Madison, WI). Data for 10
taken from Falke et al. [34].
The results of the kinase inhibition assays show that with exception of the Mannich base 16, all other
tested derivatives are inhibitors of DYRK1A with IC50 values in the low micromolar or submicromolar
concentration range. However, compared to the model compound 10, the new congeners are less
active by two orders of magnitude and are nonselective versus the closely related CLK1. In terms of
selectivity versus other CMGC kinases, congeners 11 and 12 show a considerable selectivity versus
CDKs, CK1, and GSK-3, while especially 14 and 15 appear to be rather promiscuous.
A striking result was the complete loss of DYRK1A inhibitory activity observed with the
Mannich base hydrochloride 16, since the docking analyses with this molecule had predicted favorable
orientations of both enantiomers in the ATP binding pocket of DYRK1A. To ensure that the piperidine
structure 16 is not an inactive outlier in a series of otherwise active inhibitors, we also prepared the
hydrochlorides of the morpholine and the dimethylamine analogues 27 and 28 (Figure 4). These
derivatives turned out to be inactive as DYRK1A inhibitors, too. The observed lack of inhibitory
activity is probably explained by the fact that Mannich bases like 16, 27, and 28 form intramolecular
hydrogen bonds involving the protonated amino group and the carbonyl oxygen. The existence
of the indicated hydrogen bond becomes obvious by the diasterotopic relationship of the methyl
groups in 28, which appear in the 1H NMR spectrum as two distinct singlets with 3H intensity each.
The puckered conformation resulting from the intramolecular hydrogen bonding is unable to fit into
the ATP binding pocket of DYRK1A. Prior to accommodation of these Mannich bases to the ATP
binding pocket, detachment of the intramolecular hydrogen bond would be necessary. However, the
energy for breaking the intramolecular hydrogen bond is probably not sufficiently compensated by the
new contacts formed upon binding of the Mannich base to the host protein.
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2.4. Solubility
The main objective for the design and preparation of the derivatives described here was the
generation of a selective DYRK1A inhibitor derived from 10 with improved solubility. Although
none of the new [b]-annulated indoles 12–16 showed activity or selectivity comparable to the model
compound 10, 4-chlorocyclohepta[b]indol-10(5H)-one (11) was identified as a novel submicromolar
dual DYRK1A/CLK1 inhibitor. In order to determine the suitability of 11 as chemical probe in biological
assays, its kinetic and thermodynamic solubility [40] in aqueous phosphate buffer (pH 7.4) was
evaluated and compared to both 10 and 16 (Table 2). Both KuFal194 (10) and 11 exhibited very poor
thermodynamic solubility with saturation concentrations below the limit of quantification (< 5 µM)
in the HPLC system. For standard biological assays under HTS conditions, the kinetic solubility
(the solubility of the fastest precipitating polymorph) is more relevant. Regarding this parameter,
11 displayed a fivefold improved solubility compared to 10. Although totally inactive as DYRK1A
inhibitor, the Mannich base hydrochloride 16 was also investigated for solubility. As expected, the
compound performed much better in both assays, exhibiting double digit millimolar solubility in the
thermodynamic and single digit millimolar solubility in the kinetic assay.
Table 2. Solubility data for selected [b]-annulated indoles.
Compound Sexp., therm., pH 7.4 [µM] a Sexp., kin., pH 7.4 [µM] b
KuFal194 (10) <5 5.28 (4.99–5.57)
11 <5 26.1 (25.6–26.5)
16 13,650 (11,100–16,200) 2310 *
a Thermodynamic solubility (phosphate buffer pH 7.4) using the shake-flask method. In two independent
experiments vials were incubated at 25 ◦C and quantified by HPLC. Signals lower than the limit of quantification are
indicated as <5 µM (lowest concentration used for calibration). Mean value and range are given. b Kinetic solubility
using nephelometry. Mean value and range are given. * Singlicate measurement.
2.5. Crystal Structure Analysis
To confirm the binding mode of the [b]-annulated indoles, we determined the crystal structure
of DYRK1A in complex with the representative inhibitor 11 (Table 3). The binding mode of the
inhibitor observed in the crystal structure was in agreement with the one suggested by our docking
analyses. Specifically, the flat heterocyclic core element of 11 was located in the adenine pocket and
kept in position by a hydrogen bond between its carbonyl oxygen and the ε-amino group of catalytic
Lys188. The chloro substituent was directed towards the backbone carbonyl oxygen of the hinge
Leu241. The latter topology suggests a weak halogen bond, although both the Cl···O distance (3.9 Å) as
well as the σ-hole angle (141◦) were outside or near the limits defining this non-classical interaction
(< 3.27 Å and 140◦–180◦, respectively [41]) (Figure 3c). Limited direct contacts between the kinase and
11 suggested that the inhibitor likely achieved its potency through excellent shape complementarity.
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Table 3. Data collection and refinement statistics of the DYRK1A-ligand 11 complex.
PDB Accession Code 6T6A
Data collection
beamline Diamond Light Source, i04-1
wavelength (Å) 0.9200
Resolution a (Å) 46.23–2.80 (2.95–2.80)
space group C2
cell dimensions
a (Å) 244.9
b (Å) 65.4
c (Å) 148.1
α (deg) 90
β (deg) 115.2
γ (deg) 90
no. unique reflections a 51,386 (7523)
Completeness a (%) 97.6 (98.5)
I/σI a 7.5 (2.1)
Rmerge a 0.122 (0.535)
CC(1/2) 0.991 (0.757)
Redundancy a 3.6 (3.7)
Refinement
no. atoms in refinement (P/L/O) b 11,336/48/436
Rfact (%) 20.5
Rfree (%) 24.2
Bf (P/L/O) b (Å2) 49/55/39
rmsd bond c (Å) 0.010
rmsd deviation angle c (deg) 1.4
Molprobity
Ramachandran favored 93.71
Ramachandran outlier 0.0
a Values in brackets show the statistics for the highest resolution shells. b P/L/O indicate protein, ligand molecule,
and other (water and solvent molecules), respectively. c rms indicates root-mean-square deviation.
3. Materials and Methods
3.1. General Information
The starting materials and reagents were purchased from Acros Organics (Geel, Belgium),
Alfa Aesar (Karlsruhe, Germany), and Sigma-Aldrich (Steinheim, Germany). All reagents and solvents
were used without further purification unless otherwise stated. Silica gel (40–63 µm) was used
for purification by column chromatography. Reaction monitoring was performed using thin layer
chromatography (TLC): Polygram SIL G/UV254, 0.2 mm silica gel 60, 40 × 80 mm (Macherey-Nagel,
Düren, Germany), visualization by UV light (254 nm). The melting points (m.p.) were detected in
open-glass capillaries on an electric variable heater (Electrothermal IA 9200, Bibby Scientific, Stone,
UK). The infrared spectra were recorded on a Thermo Nicolet FT-IR 200 spectrometer (Thermo Nicolet,
Madison, WI, USA) using KBr pellets. 1H NMR spectra and 13C NMR spectra were recorded on
Bruker Avance III 400, Bruker Avance II 600 or Bruker Avance III HD 500 spectrometers (Bruker
Biospin, Rheinstetten, Germany) (at the NMR laboratories of the Chemical Institutes of the Technische
Universität Braunschweig) in DMSO-d6. Chemical shifts are reported as parts per million (ppm)
relative to tetramethylsilane as internal standard (δ = 0 ppm). Signals in 13C spectra were assigned
based on results of 13C DEPT135 experiments. Electron ionization (EI) mass spectra were recorded
on a Finnigan-MAT 95 (Thermo Finnigan, Bremen, Germany), (EI) MS: ionization energy 70 eV.
Accurate measurements were performed according to the peakmatch method using perfluorokerosene
(PFK) as an internal mass reference (Department of mass spectrometry of the Chemical Institutes,
TU Braunschweig, Braunschweig, German). Atmospheric pressure chemical ionization (APCI) and
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electrospray ionization (ESI) spectra were determined with an expressionL cmS spectrometer (Advion,
Ltd., Harlow, UK), the APCI source was coupled with ASAP (atmospheric solids analysis probe).
The ESI measurements were performed by acetic acid addition in THF or ethyl acetate via direct injection.
The elemental analyses were performed on a CE Instruments Flash EA® 1112 Elemental Analyzer
(Thermo Quest, San Jose, CA, USA). If the elemental analysis was inconclusive a HRMS (described
above) study was performed. Purity was determined using high performance liquid chromatography
(HPLC) methods with isocratic or gradient elution. All compounds tested in biological systems had
purity ≥95%, if not stated otherwise. The following HPLC devices and settings were used: system 1:
Merck Hitachi Elite LaChrom system (Hitachi High Technologies Corporation, Tokyo, Japan) (diode
array detector (DAD): L-2450; pump: L-2130; autosampler: L-2200; organizer box: L-2000); system
2: VWR Hitachi Chromaster system (Hitachi High Technologies Corporation, Tokyo, Japan) (DAD
detector: 5430; column oven: 5310; pump: 5110; autosampler: 5260); column: Merck LiChroCART
125-4, LiChrospher 100 RP-18 (5 µm) (Merck, Darmstadt, Germany); system 3: Merck Hitachi Elite
LaChrom system (Hitachi High Technologies Corporation, Tokyo, Japan) detector: L-2400; pump:
L-2130; autosampler: L-2200; organizer box: L-2000); flow rate: 1.000 mL/min; detection wavelength:
254 nm and 280 nm ( isocratic), 254 nm (gradient); overall run time: 20 min (gradient), 7–60 min
(isocratic); AUC, % method; tms = retention time, tm = dead time related to DMSO. If not stated
otherwise, an acetonitrile/water mixture was used for gradient elution (0–2 min: 10% ACN; 2–12 min:
10%→90% ACN (linear) 12–20 min: 90% ACN). For isocratic elution, different acetonitrile/water or
acetonitrile/buffer mixtures were used. Absorption maxima (λmax) were extracted from the UV spectra
recorded by the DAD detector in the peak maxima during HPLC runs. For the measurements of the
purity, the thermodynamic solubility, and calibration with external standard of the Mannich bases,
a triethylamine/triethylammonium sulfate buffer (pH 2.4) was used. For its preparation, triethylamine
(20 mL) was dissolved in water (980 mL) and sodium hydroxide (242 mg) was added. The pH was
adjusted to 2.4 by adding concentrated H2SO4 dropwise. The column was equilibrated with ACN/buffer
(10/90) for 40 min. After that the desired ACN/buffer ratio (range 10/90–35/65) was adjusted.
3.2. Syntheses
3.2.1. General procedure for the synthesis of the Mannich base hydrochlorides (Procedure A)
8-Chloro-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one 26 (1 eq.) was suspended in a mixture
of 1,4-dioxane/water (1:1). The amine (3 eq.) was added and stirred for the given time at the given
temperature. After the reaction, the crude product was either recrystallized or extracted. For extraction
ethyl acetate (30 mL) was added to the reaction mixture and extracted with aq. sulfuric acid (5%, v/v,
3 × 20 mL). The combined aqueous layers were alkalized with aq. 5M NaOH. The resulting basic
phase was extracted with ethyl acetate (2 × 50 mL). The combined org. phases were washed with brine,
water and dried over anhydrous Na2SO4. After filtration and removal of the solvent under reduced
pressure, the free base (1 eq.) was dissolved in a small amount of propan-2-ol (1–5 mL). An equimolar
amount of HCl in propan-2-ol (5–6 M) was added dropwise. If no precipitate formed, diethyl ether
was added dropwise and the precipitate was filtered off.
3.2.2. Synthesis and Characterization of 11, 12, 13, 14, 15, 16, 20, 21, 22, 24, 25, 26, 27 and 28
4-Chlorocyclohepta[b]indol-10(5H)-one (11): To a solution of 4-chloro-6,7,8,9-tetrahydro-cyclohepta[b]indol-
10(5H)-one (22; 83.0 mg, 0.355 mmol) in dry THF (10 mL) phenyltrimethylammonium tribromide
(PTAB) (267 mg, 0.710 mmol) was added. After stirring the mixture for 28 h at room temperature, a
further portion of PTAB (267 mg, 0.710 mmol) was added and stirring was continued for 20 h. A
precipitate was filtered off and washed with a small portion of THF. The filtrate was evaporated and
the remaining brown oil was dissolved in DMF (5 mL). Lithium chloride (48.9 mg, 1.14 mmol) was
added and the mixture was refluxed under nitrogen for 2.5 h. Subsequent column chromatography
(toluene-ethyl acetate 1:1) yielded a brown solid (47.4 mg, 58%). M.p.: Dec. starting at 240 ◦C; IR (KBr):
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v˜ max 3434 (NH), 1631 (C=O) cm−1 (Figure S3); 1H NMR (500 MHz, DMSO-d6) δ (ppm) = 7.07 (d, J =
12.2 Hz, 1H), 7.14–7.21 (m, 1H), 7.27–7.38 (m, 2H), 7.61 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 10.9 Hz, 1H),
8.72 (d, J = 7.9 Hz, 1H), 12.77 (s, 1H, NH) (Figure S1); 13C NMR (126 MHz, DMSO-d6) δ (ppm) = 122.3,
122.7, 125.6, 126.4, 129.1, 133.0, 139.3 (CH), 115.6, 122.9, 127.9, 134.4, 142.0, 181.9 (C) (Figure S2); MS
(APCI+): m/z (%) 229.8 [M + H]+ (100), 200.8 [M − 29]+ (15.5) (Figure S4); MS (APCI−): m/z (%) 227.8
[M − H]− (100) (Figure S5); C13H8ClNO (229.66) HR-EIMS m/z [M]+• calc. 229.02889, found 229.02923
(Figure S6); HPLC (isocr.): 99.3% at 254 nm, 99.9% at 280 nm, tms = 4.2 min, tm = 1.2 min (ACN/H2O
40:60) (system 2) (Figure S8); HPLC (gradient): 97.9% at 254 nm, tms = 9.6 min, tm = 1.2 min (system 1),
λmax = 220, 238, 280, 368 nm (Figure S7).
5-Chloro-3,4-dihydrocyclopenta[b]indol-1(2H)-one (12): 5-Chloro-1,2,3,4-tetrahydrocyclopenta[b]indole
(20, 170 mg, 0.89 mmol) was dissolved in 1,4-dioxane/water (10:1, 11 mL) and stirred at 0 ◦C (ice
bath). Then 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 408 mg, 1.78 mmol) was added in small
amounts. The mixture was allowed to heat up to rt. After 3 h, the precipitating solid was collected and
dissolved in chloroform (30 mL) and washed with saturated aq. NaHCO3 (120 mL). The chloroform
layer was dried over Na2SO4 and the solvent was removed under reduced pressure. After purification
by column chromatography (toluene-ethyl acetate-diethylamine 2:2:1) a colorless solid (96 mg, 52%)
was obtained. M.p.: 280–282 ◦C; IR (KBr): v˜ max 3442 (NH), 1658 cm−1 (C=O); 1H NMR (DMSO-d6,
600 MHz) δ (ppm) = 2.84–2.87 (m, 2H, CH2), 3.09–3.12 (m, 2H, CH2), 7.18 (t, 1H, J = 7.8 Hz, Ar-H),
7.32 (dd, 1H, J = 7.8, 1.0 Hz, Ar-H), 7.64 (dd, 1H, J = 7.8, 0.9 Hz, Ar-H), 12.40 (s, 1H, NH); 13C NMR
(DMSO-d6, 151 MHz) δ (ppm) = 21.1, 40.7 (CH2), 118.3, 122.5, 122.6 (CH), 116.2, 119.8, 122.5, 138.7,
168.6, 194.9 (C=O) (C); C11H8ClNO (205.64) calc. C 64.25, H 3.92, N 6.81, found C 64.39, H 3.89, N 6.89;
HR-EIMS m/z [M]+ calc. 204.02107, found 204.02086; EIMS m/z (%) 205 (89), 204 (30), 177 (100); HPLC
(isocr.): 100% at 254 nm, 100% at 280 nm, tms = 4.8 min, tm = 1.0 min (ACN/H2O 30:70) (system 1) λmax
239, 259, 292 nm; HPLC (gradient): 98.5% at 254 nm, tms = 8.0 min, tm = 1.2 min (system 3).
8-Chloro-1,2,3,9-tetrahydro-4H-carbazol-4-one (13): 1,3-Cyclohexanedione (23, 561 mg, 5.00 mmol) was
dissolved in water (30 mL) and 2-chlorophenylhydrazine hydrochloride (17, 896 mg, 5.00 mmol) was
added in small amounts. The mixture was stirred for 24 h at rt. The resulting orange precipitate was
filtrated and washed with water and petroleum ether. After drying the precipitate at 60 ◦C for 2 h,
aq. sulfuric acid was added (20%, 100 mL). After the mixture reacted at 100 ◦C for 2 h, the solvent
was removed under reduced pressure. After recrystallization from ethanol 96%, a yellow solid (340
mg, 31%) was obtained. M.p.: 266–267 ◦C; IR (KBr): v˜ max 3139 (N=H), 1633 cm−1 (C=O); 1H NMR
(DMSO-d6, 400 MHz) δ (ppm) = 2.13 (quint, 2H, J = 6.2 Hz, CH2), 2.43–2.48 (m, 2H, CH2), 3.00 (t, 2H,
J = 6.2 Hz, CH2), 7.15 (t, 1H, J =7.7 Hz, Ar-H), 7.25 (dd, 1H, J = 7.7,1.0 Hz, Ar-H), 7.91 (dd, 1H, J = 7.7,
0.8 Hz, Ar-H), 12.19 (s, 1H, NH); 13C NMR (DMSO-d6, 101 MHz): δ (ppm) = 22.7, 23.2, 37.7 (CH2),
119.0, 122.0, 122.7 (CH), 112.5, 115.9, 126.4, 132.8, 153.5, 193.1 (C=O) (C); C12H10ClNO (219.67) calc. C
65.61, H 4.59, N 6.38, found C 65.57, H 4.68, N 6.42; EIMS m/z (%) 219 (60), 191 (100), 163 (58); HPLC
(isocr.): 99.1% at 254 nm, 99.1% at 280 nm, tms = 6.2 min, tm = 1.0 min (ACN/buffer 30:70) (system 1)
λmax 240, 265, 299 nm; HPLC (gradient): 98.9% at 254 nm, tms = 9.0 min, tm = 1.1 min (system 3).
6-Chloro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one (14): 5-Chloro-2,3-dihydrocyclopenta[b]in-
dol-1(4H)-one oxime (24, 57 mg, 0.26 mmol) was added to PPA (4 g) at 140 ◦C and stirred for 1
h. After cooling to 60 ◦C, the mixture was poured on water (100 mL) and neutralized with aq. NaOH
(2M). After extraction with ethyl acetate (3 × 50 mL) and removal of the solvent under reduced pressure,
the resulting solid was purified by column chromatography (toluene-ethyl acetate-diethylamine 2:2:1).
A yellow solid (24 mg, 42%) was obtained. M.p.: 284–286 ◦C; IR (KBr): v˜ max 3413, 3389 (NH),
1634 cm−1 (C=O); 1H NMR (DMSO-d6, 600 MHz) δ (ppm) = 2.99 (t, 2H, J = 6.9 Hz, CH2), 3.47 (dt, 2H, J
=6.9, 2.5 Hz, CH2), 7.10 (t, 1H, J = 7.8 Hz, Ar-H), 7.13 (t, 1H, J = 2.4 Hz, lactam-NH), 7.19 (dd, 1H, J =
7.7, 1.0 Hz, Ar-H), 7.82 (dd, 1H, J = 7.9, 0.8 Hz, Ar-H), 11.98 (s, 1H, indole-NH); 13C NMR (DMSO-d6,
151 MHz) δ (ppm) = 22.3, 39.7 (CH2), 118.4, 120.9, 121.6 (CH), 106.2, 115.8, 127.0,132.6, 145.6, 165.3
(C=O) (C); C11H9ClN2O (220.65); HR-EIMS m/z (%) [M]+ calc. 220.03979, found 220.03987; EIMS m/z
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(%) 220 (67), 191 (100), 163 (55); HPLC (isocr.): 99.2% at 254 nm, 99.8% at 280 nm, tms = 3.4 min, tm =
1.0 min (ACN/H2O 30:70) (system 1) λmax 252, 278 nm; HPLC (gradient): 94.3% at 254 nm, tms = 7.4
min, tm = 1.2 min (system 3).
7-Chloro-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one (15): 8-Chloro-1,2,3,9-tetrahydro4H-carb-
azol-4-one oxime (25, 100 mg, 0.426 mmol) was added to PPA (4 g) at 140 ◦C and stirred for 1
h. After cooling to 60 ◦C, the mixture was poured on water (100 mL) and neutralized with aq. NaOH
(2M). After extraction with ethyl acetate (3 × 50 mL) and removal of the solvent under reduced pressure,
the resulting solid was purified by column chromatography (toluene-ethyl acetate-diethylamine 2:2:1).
A yellow solid (45 mg, 45%) was obtained. M.p.: 261–262 ◦C; IR (KBr): v˜ max 3413, 3262 (NH), 1626
cm−1 (C=O); 1H NMR (DMSO-d6, 600 MHz) δ (ppm) = 1.97–2.03 (m, 2H, CH2), 3.14 (t, 2H, J = 6.7 Hz,
CH2), 3.21 (dt, 2H, J = 5.2, 5.0 Hz, CH2), 7.04 (t, 1H, J = 7.8 Hz, Ar-H),7.16 (dd, 1H, J = 7.6, 0.9 Hz,
Ar-H), 7.52 (t, 1H, J = 5.1 Hz, lactam-NH), 8.15 (dd, 1H, J = 8.0, 0.8 Hz, Ar-H), 11.71 (s, 1H, indole-NH);
13C NMR (DMSO-d6, 151 MHz) δ (ppm) = 26.0, 28.0, 40.7 (CH2), 120.5, 120.9, 121.0 (CH), 107.7, 114.7,
130.4, 132.3, 143.5, 167.1 (C=O) (C); C12H11ClN2O (234.68); calc. C 61.41, H 4.72, N 11.94, found C 61.11,
H 4.66, N 12.08; EIMS m/z (%) 234 (100), 191 (30), 177 (23), 163 (16); HPLC (isocr.): 100% at 254 nm,
100% at 280 nm, tms = 4.3 min, tm = 1.0 min (ACN/H2O 30:70) (system 1) λmax 281 nm.
(R,S)-8-Chloro-3-(piperidin-1-ylmethyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride (16): According
to Procedure A from 8-chloro-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one (26, 150 mg, 0.647
mmol) and piperidine (195 µL, 1.95 mmol) in 1,4-dioxane/water (1:1, 4 mL) for 16 h at 55 ◦C. After
filtration, extraction and precipitation a beige solid (130 mg, 57%) was obtained. M.p.: 215–216 ◦C; IR
(KBr): v˜ max 3420 (NH), 2619, 2515 (NH+), 1618 cm−1 (C=O); 1H NMR (DMSO-d6, 500 MHz) δ (ppm) =
1.35–1.49 (m, 1H), 1.60–1.89 (m, 5H), 1.97–2.11 (m, 1H), 2.38–2.47 (m, 1H), 2.90–3.22 (m, 6H), 3.46–3.65
(m, 3H), 7.19 (t, J = 7.8 Hz, 1H, Ar-H), 7.29 (dd, J = 7.7, 1.0 Hz, 1H, Ar-H), 7.92 (dd, J = 7.9, 1.0 Hz, 1H,
Ar-H), 9.48 (s, 1H, NH+), 12.39 (s, 1H, NH); 13C NMR (DMSO-d6, 126 MHz) δ (ppm) = 21.2, 22.0, 22.1,
22.2, 28.3, 52.5, 52.9, 56.5 (CH2), 41.2, 118.8, 122.3, 123.0 (CH), 111.6, 116.1, 126.3, 133.1, 153.7, 192.5 (C);
C18H22Cl2N2O (353.29) calc. C 61.20, H 6.28, N 7.93 found C 60.94, H 6.34, N 7.74; MS (ESI+) m/z (%)
573 [M + 221]+ (13), 555 [M + 203]+ (15), 317 [M-Cl−]+ (100), 98 [M-Cl− − 219]+ (73); HPLC (isocr.):
99.4% at 254 nm, 99.3% at 280 nm, tms = 3.3 min, tm = 1.1 min (ACN/buffer 30:70) (system 1) λmax 245,
266, 302 nm.
5-Chloro-1,2,3,4-tetrahydrocyclopenta[b]indole (20): 2-Chlorophenylhydrazine hydrochloride (17, 538 mg,
27.9 mmol) and sodium acetate (246 mg, 3.00 mmol) were dissolved in glacial acetic acid (10 mL).
Cyclopentanone (18, 0.27 mL, 3.00 mmol) was added and the reaction mixture was stirred for 1 h
at 90 ◦C (oil bath temperature). After addition of conc. H2SO4 (0.25 mL), the mixture was stirred
for an additional hour at 110 ◦C. After cooling to rt, the mixture was poured into sodium acetate
solution (5%, 20 mL). The precipitate was filtered off and purified by column chromatography (toluene).
A colorless solid (360 mg, 63%) was obtained. M.p.: 57–59 ◦C; IR (KBr): v˜ max 3385 cm−1 (NH); 1H
NMR (DMSO-d6, 400 MHz) δ (ppm) = 2.42–2.50 (m, 2H, CH2), 2.71–2.76 (m, 2H, CH2), 2.81–2.86 (m,
2H, CH2), 6.93(t, 1H, J = 7.7 Hz, Ar-H), 7.03 (dd, 1H, J = 7.7, 1.1 Hz, Ar-H), 7.28 (dd, 1H, J = 7.7, 0.9
Hz, Ar-H), 11.13 (s, 1H, NH); 13C NMR (DMSO-d6, 100.5 MHz) δ (ppm) = 24.0, 25.3, 28.2 (CH2), 116.8,
119.0, 119.4 (CH), 115.4, 118.7, 125.9,137.2, 145.8 (C); C11H9ClN (291.66); HR-EIMS m/z (%) [M]+• calc.
190.04180, found 190.04170; EIMS m/z (%) 191 (99), 190 (100); HPLC (isocr.): 89.1% at 254 nm, 95.5% at
280 nm, tms = 4.2 min, tm = 1.0 min (ACN/H2O 70:30) (system 1) λmax 235, 283 nm.
4-Chloro-5,6,7,8,9,10-hexahydrocyclohepta[b]indole (21): A mixture of (l)-tartaric acid and
N,N’-dimethylurea (30:70, 7.5 g) was melted at 70 ◦C with stirring. 2-Chlorophenylhydrazine
hydrochloride (17, 1.79 g, 10.0 mmol) and cycloheptanone (19, 1.29 mL, 10.0 mmol) were added to
the melt and stirring was continued at 70 ◦C. After 3 h, water was added and the mixture was cooled
to room temperature. A resulting brown precipitate was filtered off with suction and washed with
a small portion of water. Purification by column chromatography (hexane:ethyl acetate, 5:1) and
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crystallization (EtOH:H2O (7:3)) yielded a beige colored solid (470 mg, 2.14 mmol, 21%). M.p.: 99–101
◦C; IR (KBr): v˜ max = 3387 (NH), 2925 (CH aliph.), 734 (Cl) cm−1; 1H NMR: (400 MHz, DMSO-d6) δ
(ppm) = 1.61–1.73 (m, 4H, 2 CH2), 1.79–1.90 (m, 2H, CH2), 2.69–2.76 (m, 2H, CH2), 2.84–2.91 (m, 2H,
CH2), 6.92 (t, J = 7.7 Hz, 1H, Ar-H), 7.02 (dd, J = 7.6, 0.9 Hz, 1H, Ar-H), 7.31–7.38 (m, 1H, Ar-H), 10.96
(s, 1H, NH) ppm; 13C NMR (101 MHz, DMSO-d6) δ (ppm) = 24.3, 27.0, 28.0, 28.4, 31.4 (CH2), 116.1,
119.0 (2C) (CH), 113.3, 114.9, 116.1, 119.0 (2C), 130.5, 130.9, 139.8 (C); C13H14ClN (219.71) calc. C 71.07,
N 6.38, H 6.42, found C 71.08, N 6.18, H 6.37. MS (APCI+): m/z (%) = 220.1 [M + H]+ (100), 185.1 [M −
35]+ (59.4), 163.9 [M − 56]+ (46.3); MS (APCI−): m/z (%) = 218.1 [M − H]−(100); HPLC (gradient): 96%
at 254 nm, tms = 13.4 min, tm = 1.3 min (system 3), λmax = 221, 238, 276 nm.
4-Chloro-6,7,8,9-tetrahydrocyclohepta[b]indole-10(5H)-one (22): To a solution of 4-chloro-
5,6,7,8,9,10-hexahydrocyclohepta[b]indole 21 (70.0 mg, 0.319 mmol, 1 eq.) in a mixture of
1,4-dioxane/water (10:1; 5.5 mL) at 0 ◦C was added DDQ (145 mg, 0.638 mmol) in small portions.
The resulting reaction mixture was slowly allowed to warm up to room temperature. After 3 h,
the resulting precipitate was filtered off with suction. The filtrate was then evaporated and chloroform
(50 mL) was added to the residue. The resulting solution was washed with saturated aqueous NaHCO3
solution (50 mL), dried (Na2SO4), and evaporated. After purification by column chromatography
(toluene-ethyl acetate 5:1), the residue was isolated as colorless solid (48 mg, 64%). M.p.: 260–264 ◦C;
IR (KBr): v˜ max 3434 (NH), 1624 cm−1 (C=O); 1H NMR (DMSO-d6, 400 MHz) δ (ppm) = 1.78–1.89 (m,
2H, CH2), 1.89–1.97 (m, 2H, CH2), 2.64–2.72 (m, 2H, CH2), 3.14–3.22 (m, 2H, CH2), 7.12 (t, J = 7.8 Hz,
1H, Ar-H), 7.22 (dd, J = 7.6, 1.1 Hz, 1H, Ar-H), 8.10 (dd, J = 7.9, 1.0 Hz, 1H, Ar-H), 12.00 (s, 1H, NH);
13C NMR (DMSO-d6, 101 MHz) δ (ppm) = 21.6, 24.1, 26.6, 42.6 (CH2), 119.7, 121.7, 122.4 (CH), 114.6,
115.3, 129.0, 132.0, 150.4, 196.6 (C); C13H12ClNO (233.70) calc. C 66.81, N 5.99, H 5.18, found C 67.07, N
5.53, H 5.46. MS (APCI+): m/z (%) = 234.1 [M + H]+ (100), 164.0 [M − 70]+ (8.8), 190.0 [M − 44]+ (6.3);
MS (APCI−): m/z (%) 232.1 [M − H]− (100); HPLC (gradient): 99.1% at 254 nm, tms = 10.1 min, tm = 1.3
min (system 3) λmax 221, 240, 271, 303 nm.
5-Chloro-2,3-dihydrocyclopenta[b]indol-1(4H)-one oxime (24): 5-Chloro-2,3-dihydrocyclopenta[b]indol-
1(4H)-one (12, 76 mg, 0.37 mmol), hydroxylamine hydrochloride (104 mg, 1.48 mmol), and sodium
acetate (122 mg, 1.48 mmol) were refluxed in a mixture of ethanol (5 mL) and water (2 mL) until the
starting material was no longer detectable by tlc. Silical gel (2 g) was added and the solvent was
removed by evaporation. Isolation of the title compound by column chromatography (toluene-ethyl
acetate-diethylamine 2:2:1) yielded pale yellow crystals (22 mg, 27%). M.p.: 248–249 ◦C; IR (KBr):
v˜ max 3424 (NOH), 1658 cm−1 (C=N); 1H NMR (DMSO-d6, 400.4 MHz) δ (ppm) = 2.98–3.01 (m, 2H,
CH2), 3.11–3.15 (m, 2H, CH2), 7.09 (t, 1H, J = 7.7 Hz, Ar-H), 7.20 (dd, 1H, J = 7.8, 1.0 Hz, Ar-H), 7.47 (dd,
1H, J = 7.7, 0.9 Hz, Ar-H), 10.12 (s, 1H, NOH), 11.81 (s, 1H, NH); 13C NMR (DMSO-d6, 100.7 MHz) δ
(ppm) = 22.8, 30.8 (CH2), 118.1, 121.1 (2C) (CH), 116.0, 116.4, 122.6, 138.0, 155.2, 156.3 (C); C11H9ClN2O
(220.65); calc. C 59.88, H 4.11, N 12.70; found C 59.59, H 4.04, N 12.47; MS (EI): m/z (%) = 220 [M]+•
(100), 203 [M − OH]+ (90); HPLC (isocr.): 96.7% at 254 nm and 95.3% at 280 nm, tms = 5.0 min, tm = 1.0
min (ACN/H2O 30:70) (system 1); λmax: 222 nm und 258 nm; HPLC (gradient): 93.6% at 254 nm, tms =
8.3 min, tm = 1.2 min (ACN/H2O; 0 min:10/90; 13 min:90/10; 20 min:90/10) (system 3).
8-Chloro-1,2,3,9-tetrahydro-4H-carbazol-4-one oxime (25): 8-Chloro-1,2,3,9-tetrahydro4H-carb-azol-4- one
(13, 104 mg, 0.470 mmol), hydroxylamine hydrochloride (50 mg, 0.71 mmol), and sodium acetate
(59 mg, 0.71 mmol) were refluxed in a mixture of ethanol (5 mL) and water (2 mL) until the starting
material was no longer detectable by tlc. Silical gel (2 g) was added and the solvent was removed by
evaporation. Isolation of the title compound by column chromatography (hexane-ethyl acetate 3:2)
yielded colorless crystals (70 mg, 64%). M.p.: 214–218 ◦C; IR (KBr): v˜ max 3436 (NOH), 1630 cm−1
(C=N); 1H-NMR (DMSO-d6, 400.4 MHz) δ (ppm) = 1.92 (quint, 2H, J = 6.2 Hz, CH2), 2.66–2.72 (m, 2H,
CH2), 2.84 (t, 2H, J = 6.2 Hz, CH2), 7.04 (t, 1H, J = 7.8 Hz, Ar-H), 7.15 (dd, 1H, J = 7.7, 1.0 Hz, Ar-H),
7.84 (dd, 1H, J = 7.7, 1.0 Hz, Ar-H), 10.38 (s, 1H, NOH), 11.55 (s, 1H, NH); 13C NMR (DMSO-d6, 100.7
MHz) δ (ppm) = 21.9, 22.3, 22.5 (CH2), 119.9, 120.8 (2C) (CH), 107.6, 115.4, 126.0, 132.8, 142.7, 152.1 (C);
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C12H11ClN2O (234.68); calc. C 61.41, H 4.72, N 11.94, found C 61.24, H 4.71, N 11.68; MS (EI): m/z (%) =
234 [M]+• (100), 218 [M-O]+ (42), 190 [M − 44]+ (98), 189 [M − 45]+ (64); HPLC (isocr.): 99.7% at 254
nm and 99.7% at 280 nm, tms = 4.8 min, tm = 1.0 min (ACN/H2O 40:60) (system 1); λmax 234, 263 nm;
HPLC (gradient): 94.2% at 254 nm, tms = 9.7 min, tm = 1.1 min (ACN/H2O; 0 min:10/90; 13 min:90/10;
20 min:90/10) (system 3).
8-Chloro-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one (26): 8-Chloro-1,2,3,9-tetrahydro-4H-carb-
azol-4-one (13, 1.03 g, 4.70 mmol) was dissolved in DMF (5 mL). N,N-Dimethylmethylene iminium
chloride (500 mg, 5.34 mmol) was added and the solution was heated at 130 ◦C for 4 h. After cooling
to rt., water (25 mL) was added and the precipitate was filtered off and dried to yield a beige solid
(800 mg, 65%). M.p.: 225–227 ◦C; IR (KBr): v˜ max 3434 (NH), 1647 cm−1 (C=O); 1H NMR (DMSO-d6,
400 MHz) δ (ppm) = 2.87–2.96 (m, 2H, CH2), 3.05–3.12 (m, 2H, CH2), 5.41–5.46 (m, 1H, C=CH2), 5.91 –
5.95 (m, 1H, C=CH2), 7.19 (m, 1H, Ar-H), 7.29 (dd, J = 7.8, 1.1 Hz, 1H, Ar-H), 7.98 (dd, J = 7.7, 1.1 Hz,
1H, Ar-H), 12.34 (s, 1H, NH); 13C NMR (DMSO-d6, 101 MHz) δ (ppm) = 22.9, 30.6, 118.5 (CH2), 119.3,
122.4, 123.0 (CH), 113.1, 116.1, 126.7, 133.4, 144.11, 153.6, 182.5 (C); C13H10ClNO (231.68); HR-EIMS m/z
[M]+ calc. 231.04509, found 231.04454; EIMS m/z (%) 231 (100), 191 (34), 163 (37), 44 (30); MS (APCI+)
m/z (%) 232 [M + H]+(100), MS (APCI–): m/z (%) = 230 [M − H]− (100); HPLC (isocr.): 96.3% at 254 nm,
96.7% at 280 nm, tms = 12.4 min, tm = 1.1 min (ACN/buffer 30:70) (system 1) λmax 252, 274, 320 nm.
(R,S)-8-Chloro-3-(morpholinomethyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride (27): According to general
Procedure A from 8-chloro-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one (26, 100 mg, 0.432 mmol)
and morpholine (115 µL, 1.33 mmol) in 1,4-dioxane/water (1:1, 4 mL) for 6 h at 100 ◦C. After filtration,
extraction and precipitation a beige solid (88 mg, 58%) was obtained. M.p.: 222–224 ◦C; IR (KBr):
v˜ max 3429 (NH), 2458 (NH+), 1613 cm−1 (C=O); 1H NMR (DMSO-d6, 500 MHz) δ (ppm) = 1.98–2.09
(m, 1H), 2.36–2.44 (m, 1H), 3.10–3.15 (m, 2H), 3.15–3.25 (m, 4H), 3.50–3.59 (m, 2H), 3.67–3.73 (m, 1H),
3.79–3.87 (m, 2H), 3.95–4.02 (m, 2H), 7.20 (t, J = 7.8 Hz, 1H, Ar-H), 7.30 (dd, J = 7.8, 1.0 Hz, 1H, Ar-H),
7.88–7.95 (m, 1H, Ar-H), 9.88 (s, 1H, NH+), 12.39 (s, 1H, NH); 13C NMR (DMSO-d6, 126 MHz) δ (ppm)
= 22.1, 28.0, 51.7 (2C), 56.8, 62.9, 63.0 (CH2), 40.7, 118.8, 122.4, 123.1 (CH), 111.6, 116.1, 126.2, 133.1,
153.7, 192.4 (C); C17H20Cl2N2O2 (355.26); HR-ESIMS m/z (%) [[2M-2HCl + Na+]+ calc. 659.21623 found
659.21657, [M-HCl + Na+]+ calc. 341.10274 found 341.10254 (5), [M – Cl−]+ calc. 319.12078 found
319.12115 (100), [M-Cl − Cl−]+ calc. 285.15975 found 285.16009; MS (ESI+) m/z (%) 319 [M − Cl−]+ (22),
179 [M − Cl−-140]+ (71), 100 [M − Cl−-219]+ (100); HPLC (isocr.): 96.4% at 254 nm, 95.3% at 280 nm,
tms = 5.2 min, tm = 1.1 min (ACN/buffer 20:80) (system 1) λmax 246, 266, 303 nm.
(R,S)-8-Chloro-3-[(dimethylamino)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride (28):
According to Procedure A with 8-chloro-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one (26, 150 mg,
0.647 mmol) and dimethylamine (250 µL, 1.95 mmol) in 1,4-dioxane/water (1:1, 4 mL) for 17 h at 55 ◦C.
After filtration, extraction and precipitation a beige solid (31 mg, 15%) was obtained. M.p.: 202-203 ◦C;
IR (KBr): v˜ max 3398 cm−1 (NH), 2615 cm−1 (NH+), 1634 cm−1 (C=O), 1618 cm−1 (C=C), 1473 cm−1
(HN-C=C-C); 1H NMR (600 MHz, DMSO-d6) δ (ppm) = 1.95–2.05 (m, 1H), 2.30–2.37 (m, 1H), 2.85 (s,
3H, CH3), 2.86 (s, 3H, CH3), 3.08–3.20 (m, 4H), 3.59–3.67 (m, 1H), 7.20 (t, J = 7.7 Hz, 1H, Ar-H), 7.30 (dd,
J = 7.8, 1.0 Hz, 1H, Ar-H), 7.88–7.93 (m, 1H, Ar-H), 9.55 (s, 1H, NH+), 12.43 (s, 1H, NH); 13C NMR
(DMSO-d6, 151 MHz) δ (ppm) = 42.6, 43.4 (CH3) 22.1, 27.6, 57.5 (CH2), 40.8, 118.7, 122.4, 123.1 (CH),
111.6, 116.1, 126.2, 133.2, 153.9, 193.2 (C); C15H18Cl2N2O (313.22); HR-ESIMS m/z (%) [M − Cl−]+ calc.
277.11022, found 277.11051 (100); MS (ESI+) m/z (%) 371 [M–HCl + 95]+ (30), 277 [M − Cl−]+ (100), 145
[M-HCl − 131]+ (20), 58 [M-HCl − 218]+ (64), MS (ESI−) m/z (%) 275 [M-Cl − 2H+]- (100); HPLC (isocr.):
99.3% at 254 nm, 99.4% at 280 nm, tms = 4.7 min, tm = 1.1 min (ACN/buffer 20:80) (system 1) λmax 245,
266, 303 nm.
3.3. Molecular Docking
The program GOLD [42] (version 5.2.2) on a Windows 7 system was used for docking studies.
The crystal structure 4YLJ was downloaded from the protein data bank (pdb) [43]. Chain A was used as
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template structure because it best fulfilled the requirements for a halogen bond between the iodine atom
and a water molecule. Protein preparation was performed using the Quick preparation function of MOE
(Molecular Operating Environment, version 2015.1001) [44] by selecting the options “Use Structure
Preparation”, “Use Protonate 3D for Protonation” and “Allow ASN/GLN/HIS Flips in Protonate
3D”, “Delete Water Molecules farther then 4.5 Å from Ligand or Receptor/Ligand”, “Tether Receptor”
(Strength 10, Buffer 0.25), “Fix Atoms Farther than 8 Å from Ligands”, “Hydrogens close to Ligands will
not be Fixed” and “Refine” (RMS Gradient of 0.1 kcal/mol/Å) in the QuickPrep panel were selected for
refinement, protonation and energy minimization of the protein structure. The protein and ligand were
protonated at pH 7. The prepared protein was saved as a mol2 file. The ligands (both stereo isomers
for 16, 27, 28) were also created with MOE. The ligands were protonated with “Protonate 3D” (T = 300,
pH = 7.4, Salt = 0.1, Electrostatics: GB/VI, Dielectric: 2, van der Waals: 800R3, Cutoff (A): 15, Solvent:
80, Cutoff (A): 10; enable disconnected metal treatment) and the conformations with the lowest energy
were evaluated with “Energy Minimize” (Forcefield: Amber10:EHT, R-Field 1:80, Cutoff (8,10); Cell: No
Periodicity; Charges: The System Appears Reasonable; Constraints: Rigid Water Molecules; Gradient:
0.1 RMS kcal/mol/Å2). The conformations with the lowest energies were evaluated and saved as mol2
files. Docking runs were performed using the wizard of GOLD in the HERMES interface (version 1.6.2)
(CCDC Software Ltd., Cambridge, UK). Missing hydrogen atoms were added, and the ligands and
all water molecules distant from the binding pocket were removed from the protein structure. The
binding site was defined as a zone of 10 Å around the co-crystallized inhibitor. The implemented
scoring function chemscore_kinase was used for evaluation and ranking of the docking results. Search
efficiency was set to 200%, 10 different poses were generated, the function “generate diverse solutions”
was activated and the option “allow early termination” was turned off. For the retained water
molecules, the option “toggle” was used. Results of docking experiments were analyzed and visualized
using UCSF Chimera, version 1.12 (Resource for Biocomputing, Visualization, and Informatics at the
University of California, San Francisco, USA (supported by NIGMS P41-GM103311)) [45].
3.4. Protein Kinase Assays
Protein kinase assays with the derivatives 11–15 were carried out by radiometric methods using
protein kinases, reagents, and conditions as described before [34]. The DYRK1A inhibitory activities
of the Mannich bases 16, 27 and 28 were assayed in 384-well plates using the ADP-GloTM assay
kit (Promega, Madison, WI) according to the recommendations of the manufacturer. This assay is
a luminescent ADP detection assay that provides a homogeneous and high-throughput screening
method to measure kinase activity by quantifying the amount of ADP produced during a kinase
reaction. Briefly, the reactions were carried out in a final volume of 6 µL for 30 min at 30 ◦C in
appropriate kinase buffer, with either protein or peptide as substrate in the presence of 10 µM ATP.
After that, 6 µL of ADP-GloTM Kinase Reagent was added to stop the kinase reaction. After an
incubation time of 50 min at room temperature (rt), 12 µL of Kinase Detection Reagent was added
for one hour at rt. The transmitted signal was measured using the Envision (PerkinElmer, Waltham,
MA) microplate luminometer and expressed in Relative Light Units (RLU). In order to determine the
half maximal inhibitory concentration (IC50), the assays were performed in duplicate in the absence
or presence of increasing doses of the tested compounds. Kinase activities are expressed in % of
maximal activity, i.e. measured in the absence of inhibitor. The peptide substrate was obtained from
Proteogenix (Schiltigheim, France). RnDYRK1A-kd was assayed in buffer A with 0.033 µg/µl of the
peptide KKISGRLSPIMTEQ as substrate (buffer A: 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM
Tris-HCl pH 7.5, 50 µg/mL heparin). All data points for construction of dose response curves were
recorded in triplicate. Typically, the standard deviation of single data points was below 10%.
3.5. Determination of Thermodynamic Solubility
For determination of thermodynamic solubility [35] an aqueous phosphate buffer at pH 7.4 with
sodium chloride was used. The buffer was prepared by dissolving Na2HPO4 × 2 H2O (298 mg),
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KH2PO4 (19 mg) and NaCl (800 mg) in water (100 mL). The pH was adjusted to 7.4 by addition of aq.
hydrochloric acid (3 mol/L). The thermodynamic solubility was determined using a shake-flask method
with quantification by a buffer-HPLC method. The test compounds were added to a sealed Whatman
miniUniPrep vial (GE Healthcare, Freiburg, Germany) until the test compound showed visual solids
in aqueous phosphate buffer pH 7.4 (300 µL). The mixtures were shaken at 25 ◦C and 400 rpm for 24
and 48 h (IKA KS 3000 ic control, IKA-Werke, Staufen, Germany). For each time (24 and 48 h) two
independent measurements at two different detection wavelengths (254 and 280 nm) were determined.
After 24 h and 48 h the mixtures were inspected for remaining solids. The concentrations in the
resulting saturated solutions were quantified by isocratic HPLC with external standard calibration.
The equilibrium was considered to have been reached after 48 h if the concentration was comparable to
the 24 h measurement. For calibration, a stock solution of the test compounds in DMSO was prepared
and diluted with DMSO to suitable concentrations. The AUC at the wavelength 254 nm and 280 nm
was used for quantification. If the compounds caused signals lower than the limit of quantification,
the thermodynamic solubility was indicated as <5.0 µM, which was the lowest detectable concentration
of the calibration solutions.
3.6. Determination of Kinetic Solubility
The kinetic solubility was determined using laser nephelometry [35]. A stock solution based on the
results of the thermodynamic solubility measurement of the test compounds in DMSO was prepared.
The stock solution was diluted with DMSO to get different concentrations. The DMSO dilutions (5 µL)
were placed on a 96-well plate filled with aqueous phosphate buffer pH 7.4 (195 µL, same buffer as for
thermodynamic solubility). Two dilution series of the stock solution were measured. A blank was
determined for every measurement. The well plate was scanned by a nephelometer (Nephelostar Plus,
BMG Labtech, Ortenberg, Germany). Precipitated particles scatter the laser light which is detected by
the nephelometer. The intensity of the scattered light is assumed to be proportional to the particle
concentration in the suspension. The different concentrations were plotted versus the intensities
measured by the nephelometer. The resulting kick-off curves led directly to the kinetic solubility by
determining the intersection of the linear straight line paralleling the x axis and the linear slope.
3.7. Crystallization of DYRK1A-11 Complex, Data Collection and Structure Determination
Crystallization of the DYRK1A-11 complex was carried out as described previously[34], albeit with
using solution containing 31% PEG 400, 0.2 M lithium sulfate and 0.1 M tris, pH 7.5. Diffraction data
collected at Diamond Light Source, I04-1 were processed using Xia2 [46] and scaled with Scala [47].
Molecular replacement was performed using Phaser [48] and the coordinates of DYRK1A [34]. Model
rebuilding was performed in COOT [49], alternated with refinement in REFMAC [50]. The final
structure was validated for geometric correctness with Molprobity [51], and was deposited under
accession code 6T6A.
4. Conclusions
In the search for DYRK1A inhibitors with improved solubility based on the model compound 10,
[b]-annulated halogenated indoles were designed, synthesized and evaluated for biological activity.
Among a variety of new structures, 4-chlorocyclohepta[b]indol-10(5H)-one (11) was identified as
a new submicromolar dual DYRK1A/CLK1 inhibitor with slightly improved kinetic solubility.
A cocrystallization of 11 with DYRK1A enabled an X-ray structure analysis, which corroborated
the binding mode of the ligand as predicted by previous docking studies. Mannich base hydrochlorides
of the structurally related 8-chloro-1,2,3,9-tetrahydro-4H-carbazol-4-one (13) proved to be inactive as
DYK1A inhibitors.
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Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/22/4090/s1,
Figure S1: 1H NMR of 4-chlorocyclohepta[b]indol-10(5H)-one (11), Figure S2: 13C NMR of 4-chlorocyclohepta[b]
indol-10(5H)-one (11), Figure S3: IR of 4-chlorocyclohepta[b]indol-10(5H)-one (11), Figure S4: MS (APCI+) of
4-chlorocyclohepta[b]indol-10(5H)-one (11), Figure S5: MS (APCI-) of 4-chlorocyclohepta[b]indol-10(5H)-one
(11), Figure S6: HRMS/EIMS of 4-chlorocyclohepta[b]indol-10(5H)-one (11), Figure S7: HPLC gradient of
4-chlorocyclohepta[b]indol-10(5H)-one (11), Figure S8: HPLC isocratic of 4-chlorocyclohepta[b]indol-10(5H)-
one (11).
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